Correlation Analysis between Clusterin and Pathological Factors Related to Endometrial Hyperplasia

  • Wenjun Wu, Qingwei Hu, Peipei Zhang


This article aims to investigate the relationship between clusterin (CLU) and pathological factors related to endometrial hyperplasia. Methods a total of 110 patients treated in our hospital from July 2016 to December 2017 were selected as subjects. The CLU in the specimens of the subjects was determined by immunohistochemistry and correlated with pathological factors Record and statistics related data. Results In terms of age, the positive rate of CLU expression was 75.61% in patients ≥50 years of age, and the positive rate of CLU expression was 43.48% in patients <50 years of age. The expression rates of CLU (+) and (++) were 28.57% and 3.57%, 31.03% and 3.45%, 28.57% and 21.43% in proliferative, proliferative, atypical hyperplasia and cancerous stages, respectively,  24.00% and 68.00%, respectively, with statistical significance (P <0.05). Of the 25 patients with endometrial cancer, 5 had tumor emboli, and the rates of CLU expression (+), (++) and (-) were 0.00%, 60.00 and 40.00%, respectively. There were 20 cases of patients with CLU (+), (++) and (-) were 30.00, 70.00 and 0.00% respectively. The difference between the two groups was not statistically significant (P<0.01). In the FIGO staging of endometrial cancer, there were 14 patients with stage Ia, 21.43%, 64.29% and 14.28% of patients with CLU (+), (++) and (- Cases, the odds were 14.29%, 85.71% and 0.00% respectively; the patients in stage II were 4 cases, the odds were 50.00%, 50.00% and 0.00% respectively; there was no significant difference between the two groups (P> 0.05). There was no correlation between the degree of tumor differentiation and the infiltration of muscular layer in endometrial cancer patients. The difference was not statistically significant (P>0.05).Conclusions the development of endometrial hyperplasia is associated with the expression of Clusterin, and there is also a correlation between CLU overexpression and endometrial cancer.